| 证券代码 | IMDZ.O |
| 证券名称 | Immune Design Corp |
| 证券类型 | 美股 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | 主板 |
| 发行方式 | 公开发售 |
| 首发上市日 | 2014-07-24 |
| 首发价格(元) | 12 USD |
| 首发数量(股) | 5000000 |
| 首发募资额(元) | 60,000,000.00 USD |
| 首发主承销商 | Leerink Partners LLC,Jefferies LLC |
| 货币单位 | USD |
| 公司名称 | Immune Design Corp. |
| 注册地址 | 美国特拉华州 |
| 办公地址 | 1616 Eastlake Ave. E., Suite 310, Seattle, Washington, USA |
| 成立日期 | 2008-02 |
| 董事会主席 | - |
| 公司属地 | United States 美国 |
| 公司网址 | www.immunedesign.com |
| 电话 | +1 (206) 682-0645 |
| 传真 | +1 (206) 682-0648 |
| 公司简介 | Immune Design Corp. is a clinical-stage immunotherapy company with next-generation, diversified in vivo approaches designed to enable the body’s immune system to fight disease. Although it believes its approaches have broad potential across multiple therapeutic areas, it is focused in oncology and have designed its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells to fight cancer via distinct mechanisms. Its two lead product candidates, CMB305 and G100, utilize different immuno-oncology approaches that, it believes, address the shortcomings of existing therapies and have the potential to treat a broad patient population either as individual therapies or in combination with other mechanisms of action. It has also been executing a strategy to partner individual indications outside of oncology in infectious and allergic diseases, which provide potential downstream economics while preserving growth opportunity in the future. |